Concierge and Direct Primary Care - Overland Park, KS

DelRicht Research

Warts

Verrica Pharmaceuticals

condition

allSponsorName

CMIC

Canfield Scientific

Medidata

Veeva

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

DelRicht Research | Concierge and Direct Primary Care - Overland Park, KS

Site insights

Work at this site?

Active trials

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

Trial sponsors